GAO Appoints New Health IT Policy Committee Members

May 9, 2016
The U.S. Government Accountability Office (GAO) recently announced the appointment of three members to the Health Information Technology (HIT) Policy Committee.

The U.S. Government Accountability Office (GAO) recently announced the appointment of three members to the Health Information Technology (HIT) Policy Committee.

The American Recovery and Reinvestment Act of 2009 (ARRA) established the HIT Policy Committee and gave the Comptroller General responsibility for appointing 13 of its 20 members. The HIT Policy Committee makes recommendations to the Office of the National Coordinator (ONC) for Health IT on the development and adoption of a nationwide health information infrastructure, including standards for the exchange of patient medical information, according to the GAO.

James Ferguson, who will fil the position representing payers, is a fellow of the Institute for Health Policy and vice president of HIT Strategy and Policy at Oakland, Calif.-based Kaiser Permanente. He previously served on the ONC HIT Standards Committee.

Carolyn Petersen, who will fill the position of an advocate for patients and consumers, is senior editor for Mayoclinic.org of Mayo Clinic in Rochester, Minn.  She is a 30-year pediatric cancer survivor and has served as a consumer representative for multiple groups and is currently a member of the ethics committee of the American Medical Informatics Association.

Karen van Caulil, Ph.D, who will serve the position representing employers, is president and chief executive officer of the Florida Health Care Coalition, a business coalition on health representing 2 million individuals. 

Gene Dodaro, Comptroller General of the United States and head of the GAO, announced the new appointees. “It’s important to have the input of key stakeholders in the development of health information technology policy. A number of strong candidates expressed an interest in serving on the Committee, and the individuals being named today will bring highly valuable perspectives to the work of the Committee,” Dodaro said in a statement.

Sponsored Recommendations

Ask the Expert: Is Your Patients' Understanding Putting You at Risk?

Effective health literacy in healthcare is essential for ensuring informed consent, reducing medical malpractice risks, and enhancing patient-provider communication. Unfortunately...

Beyond the Silos: Transforming Coordinated Care Across Healthcare Systems

Coordinated healthcare is vital to delivering a high-quality patient experience, yet it has been difficult to systematize across all healthcare settings. Although it has largely...

The Healthcare Provider's Guide to Accelerating Clinician Onboarding

Improve clinician satisfaction and productivity to enhance patient care

ASK THE EXPERT: ServiceNow’s Erin Smithouser on what C-suite healthcare executives need to know about artificial intelligence

Generative artificial intelligence, also known as GenAI, learns from vast amounts of existing data and large language models to help healthcare organizations improve hospital ...

According to an Oct. 10 press release, a report by the World Health Organization (WHO) finds that vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% or 2.5 billion defined daily doses globally every year, supporting worldwide efforts to address antimicrobial resistance (AMR). While some of these vaccines are already available but underused, others would need to be developed and brought to the market as soon as possible. AMR occurs when bacteria, viruses, fungi, and parasites no longer respond to antimicrobial medicines, making people sicker and increasing the risk of illness, death and the spread of infections that are difficult to treat. AMR is driven largely by the misuse and overuse of antimicrobials, yet, at the same time, many people around the world do not have access to essential antimicrobials. Each year, nearly 5 million deaths are associated with AMR globally. Vaccines are an essential part of the response to reduce AMR as they prevent infections, reduce the use and overuse of antimicrobials, and slow the emergence and spread of drug-resistant pathogens. The new report expands on a WHO study published in BMJ Global Health last year. It estimates that vaccines already in use against pneumococcus pneumonia, Haemophilus influenzae type B (Hib, a bacteria causing pneumonia and meningitis) and typhoid could avert up to 106 000 of the deaths associated with AMR each year. An additional 543 000 deaths associated with AMR could be averted annually when new vaccines for tuberculosis (TB) and Klebsiella pneumoniae, are developed and rolled out globally. While new TB vaccines are in clinical trials, one against Klebsiella pneumoniae is in early stage of development.
dreamstime_xxl_210174616_1